v3.26.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
6 Months Ended 12 Months Ended
Nov. 30, 2025
Nov. 30, 2024
Dec. 31, 2025
May 31, 2025
Dec. 31, 2024
May 31, 2024
Dec. 31, 2023
Revenue              
Revenue         $ 431,378
Operating expenses              
Cost of healthcare services         (420,812)
Research and development expenses     (352,879)   (2,195,161)   (5,198,329)
General and administrative fees     (573,059)   (669,486)   (1,930,637)
Legal and professional fees     (1,062,346)   (803,285)   (2,538,161)
Other operating income (expenses)     170,756   (272,609)   (1,067,690)
Total operating expenses     (1,817,528)   (3,940,541)   (11,155,629)
Other (expense) income, net              
Loss on investments in marketable securities, net         (9,266)
Unrealized gain from fair value change of the long-term investments, net         6,431,088
Impairment loss of long-term investment       (1,000,000)   (77,200)
Interest expense, net     (95,713)   (146,924)   (121,145)
Gain on disposal of subsidiaries       703  
Issuance cost allocated to warrant liability     (153,189)    
Change in fair value of warrant liability     690,000    
Government subsidies       928,461   123,015
Sundry income       564   36,784
Total other income (expense), net     441,098   (217,196)   6,383,276
Income taxes        
Net loss     (1,376,430)   (4,157,737)   (4,340,975)
Net income (loss) attributable to non-controlling interests     13,160   (110,069)   1,516,328
Other comprehensive (loss) income              
Exchange differences on translation of foreign operations     (181,472)   99,785   (44,430)
Other comprehensive (loss) income     (181,472)   99,785   (44,430)
Comprehensive loss     (1,557,902)   (4,057,952)   (4,385,405)
Comprehensive (loss) income attributable to non-controlling interests     (13,160)   110,069   (1,516,328)
Comprehensive loss attributable to the shareholders of Aptorum Group Limited     (1,544,742)   (4,168,021)   (2,869,077)
Net loss attributable to Aptorum Group Limited     $ (1,363,270)   $ (4,267,806)   $ (2,824,647)
Net loss per share attributable to Aptorum Group Limited              
Basic (in Dollars per share) [1]     $ (0.19)   $ (0.78)   $ (0.62)
Net loss per common share, diluted (in Dollars per share) [1]     $ (0.19)   $ (0.78)   $ (0.62)
Weighted-average shares outstanding              
Basic (in Shares) [1]     7,351,784   5,453,103   4,521,133
Diluted (in Shares) [1]     7,351,784   5,453,103   4,521,133
DiamiR Biosciences Corp              
Revenue              
Revenue $ 130,355 $ 442,820   $ 631,729   $ 1,319,531  
Operating expenses              
Cost of healthcare services 93,016          
Research and development 197,029 401,208   650,591   1,156,860  
General and administrative 776,292 274,404   624,388   614,074  
Total operating costs and expenses 1,066,337 675,612   1,274,979   1,770,934  
Loss from operations (935,982) (232,792)   (643,250)   (451,403)  
Other (expense) income, net              
Other income 408,638          
Interest expense, net (57,157) (38,839)   82,046   48,599  
Total other income (expense), net 351,481 (38,839)   82,046   48,599  
Net loss before income taxes (584,501) (271,631)   (725,296)   (500,002)  
Income taxes (174,546) 10,901   17,939   114,403  
Net loss (409,955) $ (282,532)   (743,235)   (614,405)  
Other comprehensive (loss) income              
Net loss attributable to Aptorum Group Limited $ (409,955)     $ (743,235)   $ (614,405)  
Net loss per share attributable to Aptorum Group Limited              
Basic (in Dollars per share) $ (0.09) $ (0.06)   $ (0.17)   $ (0.14)  
Net loss per common share, diluted (in Dollars per share) $ (0.09) $ (0.06)   $ (0.17)   $ (0.14)  
Weighted-average shares outstanding              
Basic (in Shares) 4,440,891 4,440,891   4,440,891   4,440,891  
Diluted (in Shares) 4,440,891 4,440,891   4,440,891   4,440,891  
Service revenue | DiamiR Biosciences Corp              
Revenue              
Revenue $ 130,355          
Grant revenue | DiamiR Biosciences Corp              
Revenue              
Revenue $ 442,820   $ 531,729   $ 1,319,531  
Other revenue | DiamiR Biosciences Corp              
Revenue              
Revenue       $ 100,000      
[1] All per share amounts and shares outstanding for all periods have been retroactively restated to reflect APTORUM GROUP LIMITED’s 1 for 10 reverse stock split, which was effective on January 23, 2023.